Xtant Medical Announces Second Quarter 2020 Financial Results

BELGRADE, Mont., Aug. 03, 2020 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2020.

Second Quarter 2020 Financial Highlights:

  • Revenue for the second quarter of 2020 was $10.5 million, compared to $15.3 million for the prior-year period
  • Operating expenses in the second quarter of 2020 were $6.9 million, compared to $10.5 million for the prior-year period
  • Net loss incurred in the second quarter of 2020 was $2.5 million, compared to a net loss of $1.9 million for the prior-year period
  • Adjusted EBITDA for the second quarter of 2020 was $0.7 million, compared to $1.1 million for the prior-year period

“We are pleased with our second-quarter revenue performance primarily reflecting a rebound in spinal elective procedure volumes in June following sharp declines at the start of the COVID-19 pandemic,” said Sean Browne, President and CEO. “Our early actions to reduce expenses enabled us to conserve cash and rightsize our cost structure during this uncertain environment. Going forward, we believe operating as a leaner organization and improving our overall efficiencies will allow us to live our mission of ‘honoring the gift of donation, so our patients can live as full a life as possible.'”

COVID-19 Response Update

As previously announced, Xtant Medical identified four areas to maintain business continuity and emerge from the COVID-19 pandemic in a position of strength. We are committed to 1) Keeping our employees safe and healthy, (2) Conserving Cash, (3) Optimizing our production and thereby improving our inventory position, and (4) Improve our overall operational efficiency.

Second Quarter 2020 Financial Results

Total revenue for the three months ended June 30, 2020 was $10.5 million, which represents a decrease of 31.1% compared to $15.3 million in the same quarter of the prior year. The decrease in revenue is attributed primarily to the impact of COVID-19 and the sudden drop in elective procedures beginning in early March as result of the pandemic. Management anticipates that the current pandemic will impact revenue for the remainder of 2020.

Gross margin for the second quarter of 2020 was 62.2%, compared to 64.9% for the same period in 2019.

Operating expenses for the second quarter of 2020 were $6.9 million, compared to $10.5 million for the second quarter of 2019. The decrease was primarily due to a reduction in sales commissions, reduced salaries and wages, lower legal and consulting fees, reduced executive recruiting fees, and reduced legal settlement expenses, partially offset by additional stock-based compensation expense during the current year period.

Second quarter 2020 net loss was $2.5 million, or $0.19 per share, compared to second quarter 2019 net loss of $1.9 million, or $0.15 per share.

Adjusted EBITDA for the second quarter of 2020 was $0.7 million compared to $1.1 million for the same period in 2019. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash special charges, provision for losses on inventory and accounts receivable, non-cash compensation, change in warrant derivative liability, separation related expenses, and litigation settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

Conference Call

Xtant Medical will host a webcast and conference call to discuss the second quarter 2020 financial results on Monday, August 3, 2020 at 4:30 PM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations that by operating as a leaner organization and improving its overall efficiencies it will be well-positioned to manage near-term challenges and that the current pandemic will impact revenue for the remainder of 2020. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risks and uncertainities surrounding the debt restructuring transactions, including without limitation, the Company’s ability to consummate the restructuring transactions and to do so on a timely basis and its ability to maintain the listing of its common stock on the NYSE American; effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the effect of management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) on March 5, 2020 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

David Carey
Lazar FINN
Ph: 212-867-1762
Email: dcarey@finnpartners.com

(In thousands, except number of shares and par value)
As of June 30, 2020 As of December 31, 2019
Current Assets:
Cash and cash equivalents $ 3,019 $ 5,237
Trade accounts receivable, net of allowance for credit losses of $728 and doubtful accounts of $500, respectively 7,583 10,124
Inventories 19,888 16,101
Prepaid and other current assets 899 784
Total current assets 31,389 32,246
Property and equipment, net 4,256 4,695
Right-of-use asset, net 1,898 2,100
Goodwill 3,205 3,205
Intangible assets, net 486 515
Other assets 432 394
Total Assets $ 41,666 $ 43,155
Current Liabilities:
Accounts payable $ 3,072 $ 2,188
Accrued liabilities 5,894 6,632
Current portion of lease liability 408 394
Current portion of financing lease obligations 101 176
Total current liabilities 9,475 9,390
Long-term Liabilities:
Lease liability, less current portion 1,518 1,726
Long-term debt, plus premium and less issuance costs 77,531 76,244
Total Liabilities 88,524 87,360
Stockholders’ Equity (Deficit)
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.000001 par value; 75,000,000 shares authorized; 13,223,565 shares issued and outstanding as of June 30, 2020 and 13,161,762 shares issued and outstanding as of December 31, 2019
Additional paid-in capital 181,412 179,061
Accumulated deficit (228,270) (223,266)
Total Stockholders’ Equity (Deficit) (46,858) (44,205)
Total Liabilities & Stockholders’ Equity (Deficit) $ 41,666 $ 43,155
(Unaudited, in thousands, except number of shares and per share amounts)
Three Months Ended June 30,
Six Months Ended June 30,
2020 2019 2020 2019
Orthopedic product sales $ 10,493 $ 15,197 $ 25,227 $ 31,883
Other revenue 36 74 80 114
Total revenue 10,529 15,271 25,307 31,997
Cost of sales 3,979 5,365 9,144 11,278
Gross profit 6,550 9,906 16,163 20,719
Gross profit % 62.2% 64.9% 63.9% 64.8%
Operating expenses
General and administrative 2,931 4,187 7,250 8,664
Sales and marketing 3,895 6,072 10,309 12,814
Research and development 111 210 353 472
Total operating expenses 6,937 10,469 17,912 21,950
Loss from operations (387) (563) (1,749) (1,231)
Other (expense) income
Interest expense (2,054) (1,301) (3,163) (3,319)
Other (expense) income (53) (143)
Total Other (Expense) (2,054) (1,354) (3,163) (3,462)
Net Loss Before Provision for Income Taxes (2,441) (1,917) (4,912) (4,693)
Provision for income taxes
Current and deferred (23) (22) (45) (45)
Net Loss $ (2,464) $ (1,939) $ (4,957) $ (4,738)
Net loss per share:
Basic $ (0.19) $ (0.15) $ (0.38) $ (0.36)
Dilutive $ (0.19) $ (0.15) $ (0.38) $ (0.36)
Shares used in the computation:
Basic 13,223,565 13,161,762 13,199,455 13,166,136
Dilutive 13,223,565 13,161,762 13,199,455 13,166,136
(Unaudited, in thousands)
Six Months Ended June 30,
2020 2019
Operating activities:
Net loss $ (4,957) $ (4,738)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization 1,153 1,559
(Gain) loss on disposal of fixed assets (118) 92
Non-cash interest 3,149 3,272
Non-cash rent expense 8 11
Stock-based compensation 489 161
Provision for reserve on accounts receivable 204 232
Provision for excess and obsolete inventory 377 518
Changes in operating assets and liabilities:
Accounts receivable 2,290 1,403
Inventories (4,164) 955
Prepaid and other assets (153) 242
Accounts payable 884 (3,481)
Accrued liabilities (738) 728
Net cash (used in) provided by operating activities (1,576) 954
Investing activities:
Purchases of property and equipment (673) (211)
Proceeds from sale of fixed assets 106 163
Net cash used in investing activities (567) (48)
Financing activities:
Payments on financing leases (75) (277)
Costs associated with Second Amended and Restated Credit Agreement (108)
Net cash used in financing activities (75) (385)
Net change in cash and cash equivalents (2,218) 521
Cash and cash equivalents at beginning of period 5,237 6,797
Cash and cash equivalents at end of period $ 3,019 $ 7,318


(Unaudited, in thousands)
Three Months Ended June 30, Six Months Ended June 30,
 2020  2019  2020  2019
Net Loss $ (2,464) $ (1,939) $ (4,957) $ (4,738)
Other expense 1 56 6 131
Depreciation and amortization 468 783 1,153 1,559
Interest expense 2,054 1,301 3,163 3,319
Tax expense 23 22 45 45
Non-GAAP EBITDA 82 223 (590) 316
Non-GAAP EBITDA/Total revenue 0.8% 1.5% -2.3% 1.0%
Provision for losses on accounts receivable 66 138 204 232
Provision for excess and obsolete inventory 346 365 377 518
Non-cash compensation 219 39 489 161
Change in warrant derivative liability (1) (3) (7) 12
Separation-related expenses (15) 749 (37)
Field action expenses 125 125
Litigation reserve 270 800
Non-GAAP Adjusted EBITDA $ 712 $ 1,142 $ 1,222 $ 2,127
Non-GAAP Adjusted EBITDA/Total revenue 6.8% 7.5% 4.8% 6.6%

SOURCE: Globe Newswire, 3rd August 2020